Business Context and Reporting Period
Radiopharm Theranostics Limited, a foreign private issuer based in Australia, filed this Form 6-K for the month of November 2025. The filing serves to report two announcements published to the Australian Securities Exchange on November 25, 2025, regarding final director interest notices.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of corporate governance events rather than a financial performance statement.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing solely discloses the submission of final director interest notices for directors identified as "LA" and "PH."
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the report shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Verify the specific shareholding details contained in the attached exhibits (Final Director's Interest Notice - LA and PH).
- Confirm the identities of the directors referenced by the initials "LA" and "PH" against the company's current board roster.
- Review the Australian Securities Exchange (ASX) announcements dated November 25, 2025, for the full text of the director interest notices.